Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ
$14.99
▼ DOWN 3.48% (-0.54)

KEY STATISTICS

Market Cap$1.26 B
52w High$62.75
52w Low$5.95
Dividend Yield—
Frequency—
P/E-3.87
Volume700.41K
Shares Out.84.12M

COMPANY

LEADERSHIP

Jorge Santos da Silva
CHIEF EXECUTIVE
Jorge Santos da Silva

COMPENSATION 2026

Salary$762,386
Stock Awards$4,000,021
Incentive Plan Pay$0
All Other Comp.$24,922
Total$4,943,209

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 20, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
130

PRICE TARGET

Target High$50.00
Target Low$50.00
Target Median$50.00
Target Consensus$50.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

PRICE

$14.99 ▼ DOWN 3.48% (−$0.54)
$15.00$15.20$15.40$15.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM14.99

About MoonLake Immunotherapeutics

https://www.moonlaketx.com ↗

MoonLake Immunotherapeutics, founded in 2021 in Zug, Switzerland, is a clinical-stage biopharma developing Sonelokimab, a Nanobody therapy in Phase II trials for inflammatory conditions like hidradenitis suppurativa and psoriatic arthritis.

INDUSTRY

Biotechnology

A PRODUCT MOONLAKE IMMUNOTHERAPEUTICS IS KNOWN FOR

Sonelokimab
Sonelokimab

Sonelokimab, an investigational nanobody in Phase 3 trials for inflammatory diseases like hidradenitis suppurativa and psoriatic arthritis, is MoonLake Immunotherapeutics' lead asset with significant development potential.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
LLY COMPARE
NVS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$299.6M $0 ▼$299.6M ▲$299.6M

ETFS HOLDING THIS STOCK

ETFS HOLDING
31
LISTED HERE
10
RANKED BY POSITION SIZE
TCAF
0.04% · 225.0K
VHT
0.01% · 131.3K
ESML
0.04% · 81.6K
NUSC
0.04% · 37.3K
ONEQ
0.00% · 30.9K
BBC
0.50% · 16.8K
WOSC.L
0.00% · 5.8K
KBFR
0.04% · 274
USUE.DE
0.00% · 185
IGDA.L
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.49%
HOLDERS
248
TOP 12 OF 248 · RANKED BY POSITION SIZE
Bvf Inc/Il
19.8M sh · $260.32M
Deep Track Capital, LP
7.0M sh · $136.27M
Cormorant Asset Management, LP
4.5M sh · $83.52M
T. Rowe Price Investment Management, Inc.
4.3M sh · $83.34M
Janus Henderson Group Plc
3.5M sh · $64.3M
D. E. Shaw & Co., Inc.
3.4M sh · $65.53M
Logos Global Management LP
2.7M sh · $52.08M
Weiss Asset Management LP
2.6M sh · $50.27M
Avoro Capital Advisors LLC
2.0M sh · $14.34M
Citadel Advisors LLC
2.0M sh · $38.41M
Bioimpact Capital LLC
1.8M sh · $33.76M
Two Sigma Investments, LP
1.7M sh · $33.4M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Reich Kristian
Sale · 1.1K shares
2026-07-27
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Reich Kristian
Sale · 50.0K shares
2026-07-21
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Reich Kristian
Sale · 2.4K shares
2026-07-22
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Reich Kristian
Sale · 43.7K shares
2026-07-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 4
SELL 2
SECTOR PERFORM 1
13 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Leerink Partners OUTPERFORM BTIG BUY Needham BUY Wolfe Research OUTPERFORM Rothschild & Co BUY Clear Street BUY RBC Capital SECTOR PERFORM

SECTORS PEERS

PEERPRICE
ERAS$18.03COMPARE
MBX$63.00COMPARE
ABSI$8.71COMPARE
AVBP$30.17COMPARE
MGTX$13.82COMPARE
OLMA$10.27COMPARE
CTMX$3.21COMPARE
VSTM$7.22COMPARE